{"id":40004,"date":"2026-05-05T09:10:43","date_gmt":"2026-05-05T07:10:43","guid":{"rendered":"https:\/\/immunostep.com\/?p=40004"},"modified":"2026-04-28T10:55:36","modified_gmt":"2026-04-28T08:55:36","slug":"hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology","status":"publish","type":"post","link":"https:\/\/immunostep.com\/es\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/","title":{"rendered":"HLA-DR as a dynamic biomarker: limitations and new interpretations in clinical immunology"},"content":{"rendered":"

The human immune system is, by definition, dynamic. However, for many years clinical immunology has attempted to describe it using static biomarkers<\/strong>, single time-point measurements intended to summarize complex biological states into simplified values. Within this framework, HLA-DR<\/strong><\/a>, and particularly its expression on monocytes (mHLA-DR), has become one of the most widely used markers for assessing immune competence<\/strong> in critical settings such as sepsis, trauma, or acquired immunosuppression in intensive care units.<\/p>\n

Nevertheless, accumulating evidence over the last decade is forcing a reinterpretation of its role. HLA-DR can no longer be understood as a simple binary marker of immune activation or suppression. Its behavior reflects a far more complex phenomenon: a dynamic variable integrating time, inflammatory context, immune pressure, and inter-individual heterogeneity<\/strong>.<\/p>\n

From activation marker to indicator of immune competence<\/strong><\/span><\/h2>\n

Traditionally, clinicians and researchers have interpreted a decrease in monocytic mHLA-DR expression as a hallmark of immunoparalysis, particularly in septic patients. This observation has been robust and reproducible across multiple studies, and its association with secondary infections and poor outcomes has led to its incorporation into specialized clinical settings.<\/p>\n

However, this simplified view conceals a more nuanced reality. HLA-DR expression is not merely an on\/off switch between \u201cactive\u201d and \u201cinactive\u201d states, but rather the result of a regulatory network influenced by pro-inflammatory, anti-inflammatory, metabolic, and neuroendocrine signals<\/strong>.<\/p>\n

In this sense, HLA-DR does not only reflect \u201cimmune activity\u201d, but rather the functional capacity of the immune system to present antigen in a specific biological context<\/strong>.<\/p>\n

Limitations of a static interpretation<\/strong><\/span><\/h2>\n

One of the main challenges in the clinical use of HLA-DR is the reliance on single time-point measurements<\/strong>. In practice, many clinical decisions are based on isolated values compared against fixed cut-offs. However, this approach ignores a fundamental aspect: immunity is temporal<\/strong>.<\/p>\n

The same mHLA-DR value may have completely different meanings depending on the stage of the clinical course. For instance, an early decrease following an acute inflammatory insult may represent a physiological adaptive response, whereas persistent suppression in later stages reflects a state of sustained immune dysfunction<\/strong>.<\/p>\n

In addition, inter-individual variability<\/strong> introduces another layer of complexity. Genetic background, comorbidities, age, microbiota composition, and prior treatments can all modulate baseline expression and recovery capacity of HLA-DR, limiting the usefulness of universal thresholds.<\/p>\n

\n
\n
\n
\n
\n
\n
\n

A relevant technical issue further complicates this: flow cytometry protocols lack full standardization, including differences in antibodies, acquisition strategies, and analytical approaches, which hampers cross-study comparability.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

HLA-DR as a kinetic variable: a paradigm shift<\/strong><\/span><\/h2>\n

The most important conceptual shift occurs when HLA-DR is no longer interpreted as an absolute value but rather as an immunological trajectory<\/strong>.<\/p>\n

More than the level at a single time point, what appears to have greater clinical value is its temporal evolution<\/strong>. Progressive recovery of HLA-DR expression has been associated with restoration of immune competence and improved outcomes in critically ill patients. Conversely, persistently low levels indicate sustained immune dysfunction<\/strong>.<\/p>\n

This kinetic perspective transforms the role of HLA-DR: it shifts from a static diagnostic marker to a dynamic prognostic indicator<\/strong>, closer to a functional curve than a snapshot measurement.<\/p>\n

Integration into complex immune networks<\/strong><\/span><\/h2>\n

Another major evolution is the integration of HLA-DR into multiparametric immune profiling panels<\/strong>. On its own, its explanatory power is limited. However, when combined with other immune axes, its interpretative value increases significantly.<\/p>\n

Researchers now frequently analyze it alongside markers such as PD-1\/PD-L1<\/strong>, cytokine profiles reflecting pro- and anti-inflammatory balance, and detailed characterizations of immune cell subsets.This approach enables the identification of immune phenotypes that go far beyond the classical inflammation\/immunosuppression dichotomy.<\/p>\n

In this context, HLA-DR acts as a central functional node<\/strong>, reflecting the immune system\u2019s ability to mount an effective response to antigenic stimulation in a regulated environment.<\/p>\n

Therapeutic implications: guided immunomodulation<\/strong><\/span><\/h2>\n

The clinical interest in HLA-DR is not purely descriptive. Its dynamics have driven the development of biomarker-guided immunotherapeutic strategies<\/strong>.In specific contexts, particularly prolonged sepsis or acquired immunosuppression, clinicians have explored immunostimulatory therapies such as interferon gamma or GM-CSF, guided by persistently low mHLA-DR levels.<\/p>\n

This represents a paradigm shift toward precision immunology<\/strong>, where interventions are not solely based on disease classification but on real-time immune functional status.<\/p>\n

\n
\n
\n
\n
\n
\n
\n

In oncology, researchers are also investigating HLA-DR as a potential predictor of response to immunotherapy, given its role in activating innate immunity and influencing adaptive immune responses.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n

New frontiers: exosomes and immune communication<\/strong><\/span><\/h2>\n

One of the most promising emerging areas is the study of HLA-DR in the context of extracellular vesicles and exosomes<\/strong>. The presence of antigen-presenting-related molecules within these compartments suggests new mechanisms of systemic immune communication<\/strong>.<\/p>\n

This suggests that HLA-DR is not limited to classical cellular expression and may also participate in a broader intercellular signaling network that extends immune regulation beyond direct cell-to-cell interactions.<\/p>\n

Conclusion<\/strong><\/span><\/h3>\n

The conceptual evolution of HLA-DR reflects the broader transformation of clinical immunology toward more integrated and dynamic models. We have moved from a static biomarker-centric view to a framework where what matters is the functional dynamics of the immune system<\/strong>.<\/p>\n

Today, HLA-DR is no longer simply a marker of activation or suppression, but a variable that reflects the recent immunological history, current immune state, and future response capacity of the organism<\/strong>.<\/p>\n

Its true value lies not in a single measurement, but in its interpretation as part of a complex biological trajectory<\/strong>, positioning it as one of the key biomarkers in the future of precision immunology.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The human immune system is, by definition, dynamic. However, for many years clinical immunology has attempted to describe it using static biomarkers, single time-point measurements intended to summarize complex biological states into simplified values. Within this framework, HLA-DR, and particularly its expression on monocytes (mHLA-DR), has become one of the most widely used markers for […]<\/p>\n","protected":false},"author":225,"featured_media":31876,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[2033],"tags":[2561,2559,2553,2560,2170,2550,2552,2557,2556,2117,2555,2283,2551,2562,2558,2554,2563],"class_list":["post-40004","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-immunology","tag-antigen-presentation","tag-biomarker-dynamics","tag-clinical-immunology","tag-critical-care-immunology","tag-flow-cytometry","tag-hla-dr","tag-immune-biomarkers","tag-immune-dysfunction","tag-immune-monitoring","tag-immunology","tag-immunoparalysis","tag-immunotherapy","tag-mhla-dr","tag-monocyte-activation","tag-precision-medicine","tag-sepsis","tag-translational-immunology"],"yoast_head":"\nHLA-DR as a dynamic biomarker: limitations and new interpretations in clinical immunology | Immunostep Biotech<\/title>\n<meta name=\"description\" content=\"At Immunostep we have been innovating since 2001 to develop comprehensive products that contribute to improve. HLA-DR as a dynamic immmune biomarker, limitations and new interpretations in clinical immunology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HLA-DR as a dynamic biomarker: limitations and new interpretations in clinical immunology | Immunostep Biotech\" \/>\n<meta property=\"og:description\" content=\"At Immunostep we have been innovating since 2001 to develop comprehensive products that contribute to improve. HLA-DR as a dynamic immmune biomarker, limitations and new interpretations in clinical immunology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/\" \/>\n<meta property=\"og:site_name\" content=\"Immunostep Biotech\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/immunostepsl\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-05T07:10:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-28T08:55:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/02\/HLA-DRCD3-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1702\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c1ngela Cabestrero\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Immunostep\" \/>\n<meta name=\"twitter:site\" content=\"@Immunostep\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c1ngela Cabestrero\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/\"},\"author\":{\"name\":\"\u00c1ngela Cabestrero\",\"@id\":\"https:\/\/immunostep.com\/#\/schema\/person\/6f7086a7900eb41588a2465bcae5f427\"},\"headline\":\"HLA-DR as a dynamic biomarker: limitations and new interpretations in clinical immunology\",\"datePublished\":\"2026-05-05T07:10:43+00:00\",\"dateModified\":\"2026-04-28T08:55:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/\"},\"wordCount\":900,\"publisher\":{\"@id\":\"https:\/\/immunostep.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/02\/HLA-DRCD3-scaled.jpg\",\"keywords\":[\"antigen presentation\",\"biomarker dynamics\",\"clinical immunology\",\"critical care immunology\",\"flow cytometry\",\"HLA-DR\",\"immune biomarkers\",\"immune dysfunction\",\"immune monitoring\",\"immunology\",\"immunoparalysis\",\"immunotherapy\",\"mHLA-DR\",\"monocyte activation\",\"precision medicine\",\"sepsis\",\"translational immunology\"],\"articleSection\":[\"Immunology\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/\",\"url\":\"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/\",\"name\":\"HLA-DR as a dynamic biomarker: limitations and new interpretations in clinical immunology | Immunostep Biotech\",\"isPartOf\":{\"@id\":\"https:\/\/immunostep.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/02\/HLA-DRCD3-scaled.jpg\",\"datePublished\":\"2026-05-05T07:10:43+00:00\",\"dateModified\":\"2026-04-28T08:55:36+00:00\",\"description\":\"At Immunostep we have been innovating since 2001 to develop comprehensive products that contribute to improve. HLA-DR as a dynamic immmune biomarker, limitations and new interpretations in clinical immunology.\",\"breadcrumb\":{\"@id\":\"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/#primaryimage\",\"url\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/02\/HLA-DRCD3-scaled.jpg\",\"contentUrl\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/02\/HLA-DRCD3-scaled.jpg\",\"width\":2560,\"height\":1702},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/immunostep.com\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HLA-DR as a dynamic biomarker: limitations and new interpretations in clinical immunology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/immunostep.com\/#website\",\"url\":\"https:\/\/immunostep.com\/\",\"name\":\"Immunostep Biotech\",\"description\":\"Innovating to deliver high-performance technology for Research and Diagnosis\",\"publisher\":{\"@id\":\"https:\/\/immunostep.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/immunostep.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/immunostep.com\/#organization\",\"name\":\"Immunostep Biotech\",\"url\":\"https:\/\/immunostep.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/immunostep.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2021\/10\/logo-web-color.png\",\"contentUrl\":\"https:\/\/immunostep.com\/wp-content\/uploads\/2021\/10\/logo-web-color.png\",\"width\":1299,\"height\":591,\"caption\":\"Immunostep Biotech\"},\"image\":{\"@id\":\"https:\/\/immunostep.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/immunostepsl\/\",\"https:\/\/x.com\/Immunostep\",\"https:\/\/www.linkedin.com\/company\/immunostepsl\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/immunostep.com\/#\/schema\/person\/6f7086a7900eb41588a2465bcae5f427\",\"name\":\"\u00c1ngela Cabestrero\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/immunostep.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/378033e78b9b0300f6f50aeac830c5cf?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/378033e78b9b0300f6f50aeac830c5cf?s=96&d=mm&r=g\",\"caption\":\"\u00c1ngela Cabestrero\"},\"url\":\"https:\/\/immunostep.com\/es\/author\/acabestrero\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HLA-DR as a dynamic biomarker: limitations and new interpretations in clinical immunology | Immunostep Biotech","description":"At Immunostep we have been innovating since 2001 to develop comprehensive products that contribute to improve. HLA-DR as a dynamic immmune biomarker, limitations and new interpretations in clinical immunology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/","og_locale":"es_ES","og_type":"article","og_title":"HLA-DR as a dynamic biomarker: limitations and new interpretations in clinical immunology | Immunostep Biotech","og_description":"At Immunostep we have been innovating since 2001 to develop comprehensive products that contribute to improve. HLA-DR as a dynamic immmune biomarker, limitations and new interpretations in clinical immunology.","og_url":"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/","og_site_name":"Immunostep Biotech","article_publisher":"https:\/\/www.facebook.com\/immunostepsl\/","article_published_time":"2026-05-05T07:10:43+00:00","article_modified_time":"2026-04-28T08:55:36+00:00","og_image":[{"width":2560,"height":1702,"url":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/02\/HLA-DRCD3-scaled.jpg","type":"image\/jpeg"}],"author":"\u00c1ngela Cabestrero","twitter_card":"summary_large_image","twitter_creator":"@Immunostep","twitter_site":"@Immunostep","twitter_misc":{"Escrito por":"\u00c1ngela Cabestrero","Tiempo de lectura":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/#article","isPartOf":{"@id":"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/"},"author":{"name":"\u00c1ngela Cabestrero","@id":"https:\/\/immunostep.com\/#\/schema\/person\/6f7086a7900eb41588a2465bcae5f427"},"headline":"HLA-DR as a dynamic biomarker: limitations and new interpretations in clinical immunology","datePublished":"2026-05-05T07:10:43+00:00","dateModified":"2026-04-28T08:55:36+00:00","mainEntityOfPage":{"@id":"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/"},"wordCount":900,"publisher":{"@id":"https:\/\/immunostep.com\/#organization"},"image":{"@id":"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/#primaryimage"},"thumbnailUrl":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/02\/HLA-DRCD3-scaled.jpg","keywords":["antigen presentation","biomarker dynamics","clinical immunology","critical care immunology","flow cytometry","HLA-DR","immune biomarkers","immune dysfunction","immune monitoring","immunology","immunoparalysis","immunotherapy","mHLA-DR","monocyte activation","precision medicine","sepsis","translational immunology"],"articleSection":["Immunology"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/","url":"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/","name":"HLA-DR as a dynamic biomarker: limitations and new interpretations in clinical immunology | Immunostep Biotech","isPartOf":{"@id":"https:\/\/immunostep.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/#primaryimage"},"image":{"@id":"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/#primaryimage"},"thumbnailUrl":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/02\/HLA-DRCD3-scaled.jpg","datePublished":"2026-05-05T07:10:43+00:00","dateModified":"2026-04-28T08:55:36+00:00","description":"At Immunostep we have been innovating since 2001 to develop comprehensive products that contribute to improve. HLA-DR as a dynamic immmune biomarker, limitations and new interpretations in clinical immunology.","breadcrumb":{"@id":"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/#primaryimage","url":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/02\/HLA-DRCD3-scaled.jpg","contentUrl":"https:\/\/immunostep.com\/wp-content\/uploads\/2025\/02\/HLA-DRCD3-scaled.jpg","width":2560,"height":1702},{"@type":"BreadcrumbList","@id":"https:\/\/immunostep.com\/2026\/05\/05\/hla-dr-as-a-dynamic-biomarker-limitations-and-new-interpretations-in-clinical-immunology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/immunostep.com\/es\/"},{"@type":"ListItem","position":2,"name":"HLA-DR as a dynamic biomarker: limitations and new interpretations in clinical immunology"}]},{"@type":"WebSite","@id":"https:\/\/immunostep.com\/#website","url":"https:\/\/immunostep.com\/","name":"Immunostep Biotech","description":"Innovating to deliver high-performance technology for Research and Diagnosis","publisher":{"@id":"https:\/\/immunostep.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/immunostep.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/immunostep.com\/#organization","name":"Immunostep Biotech","url":"https:\/\/immunostep.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/immunostep.com\/#\/schema\/logo\/image\/","url":"https:\/\/immunostep.com\/wp-content\/uploads\/2021\/10\/logo-web-color.png","contentUrl":"https:\/\/immunostep.com\/wp-content\/uploads\/2021\/10\/logo-web-color.png","width":1299,"height":591,"caption":"Immunostep Biotech"},"image":{"@id":"https:\/\/immunostep.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/immunostepsl\/","https:\/\/x.com\/Immunostep","https:\/\/www.linkedin.com\/company\/immunostepsl\/"]},{"@type":"Person","@id":"https:\/\/immunostep.com\/#\/schema\/person\/6f7086a7900eb41588a2465bcae5f427","name":"\u00c1ngela Cabestrero","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/immunostep.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/378033e78b9b0300f6f50aeac830c5cf?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/378033e78b9b0300f6f50aeac830c5cf?s=96&d=mm&r=g","caption":"\u00c1ngela Cabestrero"},"url":"https:\/\/immunostep.com\/es\/author\/acabestrero\/"}]}},"_links":{"self":[{"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/posts\/40004"}],"collection":[{"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/users\/225"}],"replies":[{"embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/comments?post=40004"}],"version-history":[{"count":1,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/posts\/40004\/revisions"}],"predecessor-version":[{"id":40005,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/posts\/40004\/revisions\/40005"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/media\/31876"}],"wp:attachment":[{"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/media?parent=40004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/categories?post=40004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/immunostep.com\/es\/wp-json\/wp\/v2\/tags?post=40004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}